About Us

Ebovir Biotechnologie Inc. is a Quebec-based biotech focused on the AI-driven research and development of RNA-based therapeutics, mRNA vaccines, and molecular diagnostics targeting infectious diseases and cancer. With our lead R&D platform, Ebo-Pulmo™, we are developing a novel stem-loop RNA innate immune activator designed to stimulate antiviral interferon pathways. In parallel, we are engineering lung-targeted lipid nanoparticles (LNPs) for precise RNA delivery to respiratory tissues.
Backed by a dedicated scientific team and proprietary patented technologies, Ebovir is committed to advancing RNA innovation in Quebec and beyond, through active collaboration with academic institutions, clinical centers, and industry partners.

The medical R&D activities of Ebovir Biotechnologie Inc. described above are distinct from the EboScience cosmetic product line. EboScience products are for topical cosmetic use only and are not intended to diagnose, treat, or prevent any medical condition.

Ebovir Biotechnologies Inc., headquartered in Montreal, Quebec, was founded in 2021 incubated from McGill University.We are committed to driving innovation in the biotechnology field and has become a key partner to numerous biopharmaceutical companies.

Ebovir locates in the heart of Quebec’s life sciences hub — the CQIB Life Sciences Incubator. It is a member of the National Institute of Scientific Research (INRS), as well as BioQuebec and RNACanada, deeply integrated into Canada’s thriving life sciences ecosystem.

Ebovir operates one of North America’s most advanced private diagnostic laboratories in Canada (with BSL-2 and BSL-3 capabilities), offering comprehensive services for virology research and preclinical drug development. We focus on early cancer screening and whole genome sequencing (WGS), and is actively developing anti-aging and wellness products based on exosomes and lipid nanoparticles (LNPs).

Investissement Québec has recognized Ebovir as a recommended biotechnology company for Asia-Pacific market expansion, underscoring our potential for global growth.

With significant breakthroughs in the development of antiviral therapies, Ebovir was named one of Canada’s Top 10 Therapeutic Companies in 2024, highlighting its strong scientific capabilities.

Powered by world-class research platforms, we accelerate the clinical translation of precision medicine and regenerative technologies while promoting international collaboration.